ADA 2023 – Lilly unveils its triple threat

Watch out, Novo Nordisk. Lilly’s retatrutide, a so-called triple G, has bettered not only Novo’s Wegovy but Lilly’s own Mounjaro when data from three different obesity trials are compared. The project allowed obese patients to lose nearly a quarter of their bodyweight after around a year’s treatment.